Drugs / TQB2934
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07179679 | Dec 2025 → Oct 2027 expected | plasma cell myeloma | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05646758 | Mar 2023 → Oct 2024 | plasma cell myeloma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07266116 | Dec 2025 → Feb 2029 expected | AL amyloidosis | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07569757 | Jun 2026 → Dec 2028 expected | plasma cell myeloma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Regulatory 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗
此次获批的皮下注射剂型拟用于恶性浆细胞肿瘤患者的治疗。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB2934 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07179679 ↗ |
| Modality | Monoclonal antibody | “bispecific antibody” NCT07569757 ↗ |
| Route | Intravenous | “intravenous injection.” NCT05646758 ↗ |